Roberta Pachera, MBA

VP CDMO Small Molecules & Global Key Accounts at Olon
  • Claim this Profile
Contact Information
us****@****om
(386) 825-5501
Location
Italy, IT

Topline Score

Topline score feature will be out soon.

Bio

Generated by
Topline AI

You need to have a working account to view this content.
You need to have a working account to view this content.

Experience

    • Italy
    • Chemical Manufacturing
    • 700 & Above Employee
    • VP CDMO Small Molecules & Global Key Accounts
      • Sep 2022 - Present

    • Germany
    • Pharmaceutical Manufacturing
    • 1 - 100 Employee
    • VP, Global Head of Custom Synthesis
      • Sep 2021 - Sep 2022

    • Director Contract Manufacturing Europe
      • Oct 2015 - Sep 2021

    • Area Manager,Europe
      • Nov 2014 - Sep 2021

    • Italy
    • Pharmaceutical Manufacturing
    • 500 - 600 Employee
      • Jan 2014 - Sep 2021

      • Jan 2014 - Sep 2021

      • Dec 2010 - Jan 2014

      Determine and implement the commercial strategy for assigned customers and territories. Actively position Aptuit to win a significant proportion of outsourced global projects from assigned customer(s) and territories across the following Aptuit service lines: API, PDM, Drug Discovery and Lead Optimization including Preclinical Biosciences and Clinical Sciences .Aggressively pursue awareness of competitive activities., positioning and pricing, which includes specific reasons for awards and non-awards for assigned customers Show less

    • United Kingdom
    • Pharmaceutical Manufacturing
    • 700 & Above Employee
      • Nov 1996 - Jul 2010

      Manager of Synthetic Chemistry, Safety and Quality for the department. Coordinate the research goals and objectives for the staff providing leadership and direction in achieving these goals and objectives. Project leader with groups based both in UK, US, and Italy. Responsible of conducting appropriate strategy for the development of drugs including projection of budget and resources. Project lead for the successful file and WW launch of Ambrisentan (Volibris): preparation of CMC regulatory dossier for US,EU and Japan filing, managing 3rd party contract manufacturer to ensure successful validation, development of scientific understanding to successfully respond to regulatory inquiries, management of a cross-functional team including chemistry, analytical, engineering, quality, and regulatory. Responsible on behalf of the WW GSK Chemical Development Department of the technical needs of the Drug Discovery Organization for Neglected Diseases based in Spain (Madrid).Experienced in the Due Diligence process Show less

      • Mar 2006 - Jun 2008

      Team Manager with distinguished career in chemical research and R&D project management with proven track record of project delivery from early phase development to registration and launch. Impressive breadth of experience in leading early phase projects in different therapeutic area. Strong leadership skills demonstrated by managing multidisciplinary, global in the Italy, the UK, and US. A deep understanding of the Chemical and PreClinical Development global business acquired while on a long term global assignment in US (Mar2006-Jun2008) and a short term assignment in UK (Jun-Oct 98). Demonstrated ability to drive changes and implementing new way of working within the organization. Show less

Education

  • CUOA Business School
    MBA
    2010 - 2011
  • School of Management, University of Michigan - Dearborn
    marketing
    2010 - 2011
  • Alma Mater Studiorum – Università di Bologna
    chemistry, organic chemistry
    1986 - 1995

Community

You need to have a working account to view this content. Click here to join now